MiR-1180-5p regulates apoptosis of Wilms’ tumor by targeting p73
Authors Jiang X, Li H
Received 9 August 2017
Accepted for publication 19 October 2017
Published 16 February 2018 Volume 2018:11 Pages 823—831
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Xiuyun Jiang,1 Huaicheng Li2
1Neonatal Intensive Care Unit, Zhoukou Central Hospital, Zhoukou, 2Department of Internal Medicine, The People’s Hospital of Zhoukou, Zhoukou, People’s Republic of China
Introduction: Wilms’ tumor (WT), the most common childhood tumor, occurs in sporadic or familial forms. Recent findings reported that abnormal expression in microRNA (miRNA) suggests an important role of miRNAs during WT progress. MiRNAs are endogenous short-chain noncoding RNAs, which have been reported as key biomarkers for detecting tumor onset and progression. However, the functional role of miR-1180 in WT has remained unknown.
Materials and methods: MTT and clonogenic survival assays were used to detect WT cell proliferation. Flow cytometry Annexin V-FITC was used to measure apoptosis. In addition, proteins expressions in the cells were determined by Western blotting.
Results: In the present study, we demonstrated that miR-1180 is upregulated in WT when compared with adjacent tissues by quantitative reverse-transcription polymerase chain reaction. In addition, the inhibition of miR-1180 induced apoptosis in SK-NEP-1 cell line in vitro. Moreover, luciferase reporter assay showed that p73 protein was the target of miR-1180, which was confirmed by the results of Western blotting. Finally, in vivo data indicated that the tumor growth in mice was significantly inhibited by miR-1180 inhibitor.
Conclusion: Our results indicate that miR-1180 might serve as a therapeutic target for future WT therapy.
Keywords: miR-1180-5p, childhood tumor, apoptosis, p73, cell signaling, microRNA
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]